10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA
Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Financial Results, Press Release
Investor Presentation
2026 Annual Meeting of Stockholders Held by Contineum Therapeutics, Inc.
Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Annual Report to Security Holders
Earnings Release
News
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report